Clinical Characteristics and Management for Flares in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs
International Journal of Rheumatic Diseases · 2026
DOI: 10.1111/1756-185x.70631 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, 2026. Verfasst von Young-Eun Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Biological Products. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Asan Institute for Life Sciences, Asan Medical Center.
Abstract (Originalsprache)
Objective
To evaluate the frequency and management of flares in rheumatoid arthritis (RA) patients treated with biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs).
Methods
Data were analyzed from the KOrean nationwide BIOlogics (KOBIO) registry, which includes RA patients initiating b/tsDMARDs therapy. Flares were defined as an increase in DAS28 (> 1.2, or > 0.6 if DAS28 ≥ 3.2) requiring medication changes. Patients were stratified by flare occurrence, and predictive factors and management strategies were assessed.
Results
Of the 2745 RA patients, 386 (14.1%) experienced flares over a median follow‐up period of 5.4 years (IQR, 1.7–11.4). Flares were associated with a significantly higher incidence of shoulder swelling compared with non‐flare patients (14.2% vs. 13.7%, p = 0.01). Predictive factors for flares included a higher swollen joint count (HR: 1.125, p = 0.003) and shoulder swelling (HR: 2.810, p = 0.002). Eight patients switched to an alternative b/tsDMARD during flare episodes, while 168 added or modified conventional synthetic DMARDs (csDMARDs). The remaining 210 patients made no changes to their csDMARD regimen. The 12 month retention rate of b/tsDMARDs did not significantly differ between patients who adjusted their csDMARDs and those who did not (86.7% vs. 82.1%, p = 0.23). However, the mean steroid dose over 12 months was lower in the group that adjusted csDMARDs.
Conclusions
Flares occurred in approximately 14% of RA patients during b/tsDMARD treatment, with baseline joint involvement, particularly shoulder swelling, being a predictor. While the adjustment of csDMARDs was associated with reduced steroid use during flare management, it did not significantly affect b/tsDMARD retention rates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Information Medicine, Big Data Research Center, Asan Medical Center, Seoul, Republic of Korea.
ORCID-Profile: Seokchan Hong
Förderung
- Asan Institute for Life Sciences, Asan Medical Center
Zitieren
APA
Kim, Y. E., Ahn, S. M., Oh, J. S., Kim, Y. G., Lee, C. K., Yoo, B., & Hong, S. (2026). Clinical Characteristics and Management for Flares in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.70631
Vancouver
Kim YE, Ahn SM, Oh JS, Kim YG, Lee CK, Yoo B, et al. Clinical Characteristics and Management for Flares in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs. International Journal of Rheumatic Diseases. 2026. doi:10.1111/1756-185x.70631
BibTeX
@article{Kim2026,
author = {Kim, Young-Eun and Ahn, Soo Min and Oh, Ji Seon and Kim, Yong-Gil and Lee, Chang-Keun and Yoo, Bin and Hong, Seokchan},
title = {Clinical Characteristics and Management for Flares in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs},
journal = {International Journal of Rheumatic Diseases},
year = {2026},
doi = {10.1111/1756-185x.70631}
}
EUVIMED